Ensysce Biosciences

ENSC

Market cap $1.99M

~ Underscores Strategic Execution Plans, Regulatory Risk Mitigation Efforts, Pipeline Prioritization, and the Commercial Potential of PF614 ~ SAN DIEGO, CALIFORNIA / ACCESS Newswire / March 4, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company pioneering next-generation pain and central nervous system therapeutics designed to minimize risk of abuse and overdose, today announced the successful initiation of its live "Ask Me Anything" (AMA) series on March 4, 2024.The event reinforced the Company's commitment to transparency, accessibility, and open dialogue with its community. A replay of the AMA series is available on the Company's website here.

~ Phase 1 Data Published in Journal of Opioid Management Validates First-in-Class Overdose-Limiting Opioid Technology of PF614-MPAR ~ SAN DIEGO, CA / ACCESS Newswire / March 3, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company pioneering next-generation pain and central nervous system therapeutics designed to minimize risk of abuse and overdose, today announced the publication of the first clinical manuscript describing its MPAR® (Multi-Pill Abuse Resistance) overdose protection technology. The paper, titled "Formulation and a Phase 1 Clinical Study of PF614-MPAR, an Oxycodone Prodrug with Oral Opioid Overdose Protection," appears online in the Journal of Opioid Management Jan/Feb 2026 issue.

Ensysce Biosciences (NASDAQ: ENSC) shares are up on Friday as the company has initiated a review of strategic alternatives aimed at enhancing shareholder value.

Review Includes Strategic Partnerships, Licensing and Other Corporate Transactions Focused on Advancing TAAPTM and MPAR® Platforms  SAN DIEGO, CALIFORNIA / ACCESS Newswire / February 25, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for novel therapeutics while reducing the potential for abuse and overdose, today announced its Board of Directors has initiated a formal review of a broad range of strategic alternatives intended to enhance shareholder value and support the continued advancement of the Company's proprietary technologies. Potential strategic alternatives may include, among other things, strategic partnerships, licensing arrangements, capital formation transactions, business combinations, asset sales or other corporate transactions.

~ Company leadership to highlight TAAP and MPAR programs, discuss innovation in pain therapeutics and present on commercial excellence ~ SAN DIEGO, CALIFORNIA / ACCESS Newswire / February 23, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for novel therapeutics while reducing the potential for abuse and overdose, today announced that members of its executive management team including Dr. Lynn Kirkpatrick, Dr. William Schmidt and Mr. Geoff Birkett have been invited to participate in upcoming scientific and industry events focused on next-generation pain therapeutics, substance use disorder research and commercial best practice.

~ Engineered to Deliver Potent Pain Relief with Built-In Abuse Protection ~ SAN DIEGO, CA / ACCESS Newswire / January 28, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company pioneering novel solutions for severe pain with built-in abuse and overdose protection, today announced it has enrolled 50% of subjects targeted for interim review in its pivotal Phase 3 clinical trial of PF614, the Company's next-generation opioid candidate engineered to deliver powerful pain relief with built-in abuse protection.. Enrollment began in late December 2025 and is progressing rapidly across three U.S. clinical sites: CenExel JBR (Salt Lake City, Utah); CenExel Atlanta (Decatur, Georgia); and ERG-HD Research, LLC (Houston, Texas).

~ TAAP™ and MPAR® technologies extended across opioid products to advance safer pain treatment ~ SAN DIEGO, CALIFORNIA / ACCESS Newswire / January 21, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for novel therapeutics while reducing the potential for abuse and overdose, today announced it received a Notice of Allowance from the Brazilian Patent Office for the issuance of a patent* covering additional opioid families, utilizing the Company's proprietary TAAP™ (Trypsin Activated Abuse Protection) and MPAR® (Multi-Pill Abuse Resistance) technologies. The newly allowed patent includes both composition of matter and method of use claims, further strengthening Ensysce's intellectual property estate and expanding its global protection for Next Generation analgesics.

~ New ADHD pipeline leverages TAAP™ and MPAR® technologies to improve safety for patients ~ SAN DIEGO, CALIFORNIA / ACCESS Newswire / January 8, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for novel therapeutics while reducing the potential for abuse and overdose, today announced it received a Notice of Allowance from the European Patent Office for the issuance of a patent* for PF8026, a groundbreaking Attention-Deficit/Hyperactivity Disorder (ADHD) therapy. PF8026 is a novel immediate-release amphetamine prodrug protected by the Company's proprietary TAAP™ (Trypsin Activated Abuse Protection) and MPAR® (Multi-Pill Abuse Resistance) technologies.

Ensysce Biosciences, Inc. (ENSC) Shareholder/Analyst Call Prepared Remarks Transcript

PF614-301 Phase 3 Trial Enrollment Underway, Advancing Toward Market Launch FDA Aligned with ENSC Manufacturing Path for PF614, Enabling Commercial Scale Up MPAR® Patent Protection Extended Through 2042 Up to $20 Million in Funding Secured to Advance Late-Stage Programs SAN DIEGO, CALIFORNIA / ACCESS Newswire / January 5, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today issued its 2025 annual letter to shareholders from Chief Executive Officer, Dr. Lynn Kirkpatrick. Dear Fellow Shareholders, 2025 was a year of meaningful execution and strategic advancement for Ensysce.